Nature SciCafé | RNA as a Therapy
JLABS , 3210 Merryfield Row , San Diego , CA 92121
June 04, 2015 from 16:30 PM to 20:30 PM (PDT)
$10 - $35
Thursday, June 4, 2015
2:30 to 6:30 p.m.
JLABS San Diego
Theme: RNA Therapeutics
The SciCafés bring together leading academic faculty with local R&D and business leaders from industry and life science ventures to discuss key challenges in translational research.
Panel Discussion: RNA as a Therapy
Since antisense therapy was first marketed in the 1990s, a dizzying array of RNA therapeutics have entered commercial development, including siRNAs, small activating RNAs, antagomirs, apatamers and even RNA-guided nucleases (CRISPRs). At the beginning of the year, Moderna Therapeutics, which is developing a synthetic mRNA platform, raised $450 million- the biggest private biotech round ever. Compared with small molecules, antibody and protein drugs, different RNA therapeutic modalities exhibit varying strengths and weaknesses in terms of accessible target biology, mode of action, chemistries, toxicities, PK/PD and delivery. This panel brings together academic and industry leaders in the nucleic acid therapy field to discuss the pros and cons of RNA as a drug and its potential to tackle unmet needed and new therapeutic areas.
2:30pm - 3:00pm | Registration & Networking
3:00pm - 5:00pm | Presentations & Panel
5:00pm - 6:30pm | Networking Reception
Moderator: Andrew Marshall | Editor, Nature Biotechnology read bio»
Pad Chivukula | CSO, Arcturus Therapeutics read bio»
Stan Crooke | CEO, Isis Pharmaceuticals read bio»
Steve Dowdy | Professor Cellular & Molecular Medicine, UC San Diego read bio»
Mark Kay | Professor of Genetics, Stanford University read bio»
3210 Merryfield Row
San Diego, CA
Padmanabh (Pad) Chivukula Ph.D. is Founder, Chief Scientific Officer, Chief Operating Officer and Director of Arcturus Therapeutics. He is responsible for Arcturus's research and development activities, including clinical and non-clinical development and regulatory affairs for all of Arcturus's medicines in development. Dr. Chivukula has an exceptional and technically solid foundation in nanoparticle technology. Prior to Arcturus, from 2008 until February 2013, Dr. Chivukula was employed by Nitto Denko Technical Corporation, a pharmaceutical company, where his titles included Group Leader and Chief Scientist. Dr. Chivukula brings over 15 years of experience in drug delivery and therapeutic drug development, including leading the polymeric RNAi research department at Nitto Denko. Dr. Chivukula has a PhD in Pharmaceutical Chemistry from the University of Utah where he specialized in nanoparticle technology.
Stanley Crooke, M.D., Ph.D. has been an Executive Chairman of Isis Pharmaceuticals, Inc. Since February 1991, and has been its Chief Executive Officer since January 1989. Dr. Crooke serves as the President of Isis Pharmaceuticals, Inc. He serves as an Editor-in-Chief of Current Opinion in Anticancer Drugs and Section Editor for Biologicals and Immunologicals for Expert Opinion on Investigational Drugs. Dr. Crooke founded Isis Pharmaceuticals, Inc. in 1989 and served as its President from January 1989 to May 1994. He served as the President of Research and Development for SmithKline & French Laboratories at SmithKline Beckman Corporation (AKA GlaxoSmithKline LLC) from 1980 to January 1989. Dr. Crooke is a Member of the San Diego State University BioScience Center Scientific Advisory Board, the Current Drugs Advisory Board, and the Editorial Board of Gene Therapy and Molecular Biology. Dr. Crooke serves as an Adjunct Professor of Pharmacology at the University of California, San Diego, and San Diego State University. In 2006, he was named in Nature Biotechnology as one of biotechnology's influential individuals. Dr. Crooke received his Ph.D. in Pharmacology and M.D. from Baylor College of Medicine, Houston, Texas and B.S. in Pharmacy from Butler University, Indianapolis, Indiana.
Steve Dowdy, Ph.D. is a Professor of Cellular & Molecular Medicine at the University of California, San Diego (UCSD) School of Medicine, Co-Founder of Solstice Biologics and an Alumnus of the Howard Hughes Medical Institute (HHMI). Previously, Dr. Dowdy was an Assistant Investigator of HHMI and Assistant Professor of Pathology and Medicine at Washington University School of Medicine. His research revolves around understanding the molecular basis of G1 cell cycle progression, how it is deregulated during oncogenesis, and synthesis and delivery of next-generation siRNN RNAi anticancer therapeutics. Dr. Dowdy is a Board Director and serves as the Chair of the Scientific Advisory Board at Solstice Biologics. He has been a Member of Scientific Advisory Board of Revance Therapeutics Inc. since 2006, and also served on the Scientific Advisory Boards of Alcon Research Labs, Ansata Therapeutics, Kai Pharmaceuticals, and Traversa Therapeutics. Dr. Dowdy received his Ph.D. from the University of California, Irvine, where he studied with Dr. Eric Stanbridge. He did his postdoctoral research with Dr. Robert Weinberg at the Whitehead Institute, MIT.
Mark Kay, M.D., Ph.D. is the Director of the Program in Human Gene Therapy, and Professor in the Department of Pediatrics and Genetics at Stanford University School of Medicine. Dr. Kay is one of the founders of the American Society of Gene Therapy and served as its President in 2005-2006. Dr. Kay received the E. Mead Johnson Award for Research in Pediatrics in 2000 and was elected to the American Society for Clinical Investigation in 1997. He has organized many national and international conferences including the first Gordon Conference related to gene therapy.Kay is respected worldwide for his work in gene therapy for hemophilia and viral hepatitis. He is an Associate Editor of Human Gene Therapy and Molecular Therapy, and a member of the editorial boards of other peer-reviewed publications. At Stanford University, Dr. Kay is involved in many committees, including the Administrative Panel on Biosafety Committee, and Chair of the Berry Foundation Committee. Along with his work in Gene Therapy Dr. Kay is an avid photographer and enjoys spending time outdoors photographing wildlife.
Andrew Marshall, Ph.D. has been Chief Editor of Nature Biotechnology since 2000. In the intervening period, the journal's impact factor has risen from 11.4 to 31.1. As well as frequently speaking on biotechnology issues at international meetings, he regularly heads and organizes conferences and symposia for Nature Publishing Group, including the acclaimed SciCafe series that brings together industry R&D leaders, investors and up-and-coming academic investigators in Boston, New York, Houston, San Diego, San Francisco and Singapore. He has more than 20 years of experience in scientific publishing and was previously Editor of Current Opinion in Biotechnology from 1992 to 1996. Adrew has written over 150 articles and editorials on science and technology for the popular media, including The Economist and Popular Science, and for trade publications. In 2003, he launched Bioentrepreneur (www.nature.com/bioent), a free-access web portal that provides practical information and advice on the challenges of starting a biotechnology company. He obtained his Ph.D. and postdoctoral experience in molecular biology and microbiology at King's College London. He is the recipient of the Helen White Prize.